Galanin peptide family regulation of glucose metabolism.


Journal

Frontiers in neuroendocrinology
ISSN: 1095-6808
Titre abrégé: Front Neuroendocrinol
Pays: United States
ID NLM: 7513292

Informations de publication

Date de publication:
01 2020
Historique:
received: 23 07 2019
revised: 09 10 2019
accepted: 25 10 2019
pubmed: 11 11 2019
medline: 21 5 2021
entrez: 10 11 2019
Statut: ppublish

Résumé

Recent preclinical and clinical studies have indicated that the galanin peptide family may regulate glucose metabolism and alleviate insulin resistance, which diminishes the probability of type 2 diabetes mellitus. The galanin was discovered in 1983 as a gut-derived peptide hormone. Subsequently, galanin peptide family was found to exert a series of metabolic effects, including the regulation of gut motility, body weight and glucose metabolism. The galanin peptide family in modulating glucose metabolism received recently increasing recognition because pharmacological activiation of galanin signaling might be of therapeutic value to improve insuin resistance and type 2 diabetes mellitus. To date, however, few papers have summarized the role of the galanin peptide family in modulating glucose metabolism and insulin resistance. In this review we summarize the metabolic effect of galanin peptide family and highlight its glucoregulatory action and discuss the pharmacological value of galanin pathway activiation for the treatment of glucose intolerance and type 2 diabetes mellitus.

Identifiants

pubmed: 31705911
pii: S0091-3022(19)30061-5
doi: 10.1016/j.yfrne.2019.100801
pii:
doi:

Substances chimiques

GAL protein, human 0
Galanin-Like Peptide 0
Peptide Hormones 0
Receptors, Galanin 0
SPX protein, human 0
alarin 0
Galanin 88813-36-9
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100801

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Auteurs

Penghua Fang (P)

Department of Physiology, Nanjing University of Chinese Medicine Hanlin College, Taizhou 225300, China.

Mei Yu (M)

Department of Physiology, Nanjing University of Chinese Medicine Hanlin College, Taizhou 225300, China.

Mingyi Shi (M)

Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou 225001, China; Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou 225001, China.

Ping Bo (P)

Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou 225001, China; Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Medical College, Yangzhou University, Yangzhou 225001, China.

Zhenwen Zhang (Z)

Department of Endocrinology, Clinical Medical College, Yangzhou University, Yangzhou 225001, China. Electronic address: zwzhang@yzu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH